122 related articles for article (PubMed ID: 31116024)
1. Identification of critical pathways and hub genes in
Sun J; Zhang K; Cai Z; Li K; Zhao C; Fan C; Wang J
Biomark Med; 2019 Jul; 13(10):831-840. PubMed ID: 31116024
[No Abstract] [Full Text] [Related]
2. Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis.
Sun J; Li S; Wang F; Fan C; Wang J
BMC Med Genet; 2019 Dec; 20(1):191. PubMed ID: 31791268
[TBL] [Abstract][Full Text] [Related]
3. In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer.
Baruah MM; Sharma N
Med Oncol; 2019 Apr; 36(5):43. PubMed ID: 30937635
[TBL] [Abstract][Full Text] [Related]
4. Significance of
Hou Y; Tan S; Wang G
Genet Test Mol Biomarkers; 2021 May; 25(5):346-354. PubMed ID: 33956533
[No Abstract] [Full Text] [Related]
5. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer.
Xu X; Xie L; Meng L; Geng S; Liu J; Cao X; Dong Z; Xing Z
Biosci Trends; 2022 Jul; 16(3):221-229. PubMed ID: 35768267
[TBL] [Abstract][Full Text] [Related]
6. Integrated Analysis Revealed Prognostic Factors for Prostate Cancer Patients.
Che H; Liu Y; Zhang M; Meng J; Feng X; Zhou J; Liang C
Med Sci Monit; 2019 Dec; 25():9991-10007. PubMed ID: 31876269
[TBL] [Abstract][Full Text] [Related]
7. Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.
Foj L; Filella X
Pathol Oncol Res; 2019 Oct; 25(4):1445-1456. PubMed ID: 30367364
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
9. Identification of key pathways and genes in
Huang R; Liao X; Li Q
Onco Targets Ther; 2018; 11():163-173. PubMed ID: 29343974
[TBL] [Abstract][Full Text] [Related]
10. TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.
Kaur HB; Lu J; Guedes LB; Maldonado L; Reitz L; Barber JR; De Marzo AM; Tomlins SA; Sfanos KS; Eisenberger M; Schaeffer EM; Joshu CE; Lotan TL
Hum Pathol; 2019 May; 87():95-102. PubMed ID: 30851334
[TBL] [Abstract][Full Text] [Related]
11. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of
Guedes LB; Almutairi F; Haffner MC; Rajoria G; Liu Z; Klimek S; Zoino R; Yousefi K; Sharma R; De Marzo AM; Netto GJ; Isaacs WB; Ross AE; Schaeffer EM; Lotan TL
Clin Cancer Res; 2017 Aug; 23(16):4693-4703. PubMed ID: 28446506
[No Abstract] [Full Text] [Related]
12. Significance of TP53 mutation in bladder cancer disease progression and drug selection.
Wu G; Wang F; Li K; Li S; Zhao C; Fan C; Wang J
PeerJ; 2019; 7():e8261. PubMed ID: 31871844
[TBL] [Abstract][Full Text] [Related]
13. Introduction of mutant TP53 related genes in metabolic pathways and evaluation their correlation with immune cells, drug resistance and sensitivity.
Motlagh AV; Mahdevar M; Mirzaei S; Entezari M; Hashemi M; Hushmandi K; Peymani M
Life Sci; 2022 Aug; 303():120650. PubMed ID: 35667517
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H
EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723
[TBL] [Abstract][Full Text] [Related]
15. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
16. Identification of key genes in prostate cancer gene expression profile by bioinformatics.
Lu W; Ding Z
Andrologia; 2019 Feb; 51(1):e13169. PubMed ID: 30311263
[TBL] [Abstract][Full Text] [Related]
17. A CD24-p53 axis contributes to African American prostate cancer disparities.
Liu W; Zhang Y; Wei S; Bae S; Yang WH; Smith GJ; Mohler JL; Fontham ETH; Bensen JT; Sonpavde GP; Chen GY; Liu R; Wang L
Prostate; 2020 May; 80(8):609-618. PubMed ID: 32168400
[TBL] [Abstract][Full Text] [Related]
18. Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis?
Roy-Burman P; Zheng J; Miller GJ
Mol Med Today; 1997 Nov; 3(11):476-82. PubMed ID: 9430782
[TBL] [Abstract][Full Text] [Related]
19. Significance of tumor protein p53 mutation in cellular process and drug selection in brain lower grade (WHO grades II and III) glioma.
Guo CF; Zhuang Y; Chen Y; Chen S; Peng H; Zhou S
Biomark Med; 2020 Aug; 14(12):1139-1150. PubMed ID: 32664789
[No Abstract] [Full Text] [Related]
20. Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer.
Moon S; Balch C; Park S; Lee J; Sung J; Nam S
IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(5):1693-1701. PubMed ID: 29994072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
